$TDAY

USA Today (NYSE:TDAY) Hits New 52

USA Today Co. (NYSE:TDAY) shares hit a new 52-week high on Wednesday, trading up to $7.82 and last at $7.75 versus a prior close of $7.73, with 37,301 shares traded. Analysts cited include a Citigroup neutral and a Rosenblatt sell; MarketBeat reports an average “Hold” and $7.70 consensus target. The company reported Feb. 26 quarterly EPS of ($0.21) on $585M revenue.

Original reporting
Published May 27, 2026, 4:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 4:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
USA Today (NYSE:TDAY) Hits New 52 — source image
Decision brief

The 30-second read

$TDAYBullishMed
01

Why it matters

For TDAY, the immediate trading signal is breakout momentum; the longer-term debate is whether valuation and balance-sheet liquidity justify sustained rerating.

02

Market read

TDAY is trading on momentum (52-week high) plus mixed sell-side sentiment; the setup favors tactical trading but not a clear fundamental re-rating signal from new data.

03

What to watch

No new earnings were reported in this article; traders should watch whether volume/price holds after the initial breakout and whether the prior-quarter EPS/revenue trend supports the valuation.

Relevance 8/10Timing: Immediate (intraday 52-week high) with potential continuation over the next several sessions as analyst notes circulate.

Background

The article frames USA Today’s move as a fresh 52-week high alongside a cluster of analyst rating changes and a reminder of the last reported quarterly EPS/revenue.

Company-level read

Ticker impact

$TDAYBullishMedium confidence
Context

USA Today shares hit a new 52-week high and the article cites multiple analyst rating/target changes affecting near-term sentiment.

Expected impact

Likely short-term bid/volatility as traders react to momentum plus recent upgrades/targets; follow-through depends on whether the stock can hold above the recent high.

Evidence & confidence

The piece provides a concrete price action catalyst (52-week high) and several analyst revisions, but it does not add new operating/earnings surprises beyond referencing the prior quarter.

Market effects

Limited read-across for media/publishing; this is primarily company-specific momentum plus analyst sentiment rather than an industry shock.

None indicated; the story is US-listed and does not reference regional demand or regulation.

Low; no international operations or global macro/regulatory driver is mentioned.

Counterpoint

The new high may be driven by positioning/analyst chatter rather than fundamentals; the article’s high P/E and weak current ratio could cap upside.

Key entities

  • USA Today Co.

    NYSE-listed publisher whose shares reached a new 52-week high and is subject to multiple analyst rating/target updates.

  • Citigroup

    Reissued a “neutral” rating in the article, tempering the bullishness from other upgrades.

  • Rosenblatt Securities

    Began coverage with a “buy” rating and a $10 target, supporting upside expectations.

Related articles

$TDAYMed

USA Today Q2 Earnings Call Highlights

USA TODAY Media, part of Gannett (NYSE: GCI), reported Q2 digital-only subscription revenue up 6.8% to $45.6M and digital-only ARPU up 34.4% to a record $10.47. Digital other revenue rose 20.2% to $20.4M. Management discussed AI licensing, DeeperDive usage, and a Palantir project for first-party data, with no benefit included in the current full-year forecast.

$TDAYMed

USA TODAY Co. Announces Second Quarter Results & Reiterates Business Outlook

USA TODAY Co., Inc. (TDAY) filed an SEC Form 8-K — Results of Operations and Financial Condition. USA TODAY Co. Announces Second Quarter Results & Reiterates Business Outlook NEW YORK, NY — August 6, 2026 — USA TODAY Co., Inc. ("USA TODAY Co.", "we", "us", "our", or the "Company") (NYSE: TDAY) today reported its financial results for the second quarter ended June 30, 2026. "T

$LLYMed

Orforglipron Noninferior for CV Outcomes in T2D

Eli Lilly's orforglipron met noninferiority criteria for CV outcomes in a phase 3 trial, showing improvements in glycemia and bodyweight. The drug was approved in the US for weight management and is under review for T2D treatment. The trial compared orforglipron to insulin glargine, with 4.2% of patients on orforglipron experiencing major adverse CV events vs 5.0% on glargine. Orforglipron showed superiority in A1c and body weight reduction but not in MACE-3 outcomes.

$LLYMed

Retatrutide results: weight loss, side effects, cost, and access

Eli Lilly's experimental obesity drug, retatrutide, showed significant weight loss in late-stage trials. Lilly plans to seek FDA approval in early 2025. The drug is already being sold online for up to $600 per vial. Cost and side effects are major reasons people stop taking obesity drugs. Insurers and states have reduced coverage, leading drugmakers to sell directly to patients. Dr. Fatima Cody Stanford highlights the need for more research on the drug's long-term effects and safety.